Minocycline in EAE Model with CD4+ Immune Cells
Minocycline treatment showed an immediate reduction in clinical signs and severity of experimental autoimmune encephalomyelitis (EAE), specifically affecting CD4+CD11bc+ immune cells. The treatment also decreased nitric oxide and reactive oxygen species production in macrophages in vitro. Notably, these effects were observed even without Nrf2 activation in knockout mice.
- Tags
- #MSResearch
- Most relevant to
- —
Why it matters
These findings suggest that minocycline might influence immune cell behavior and clinical outcomes in autoimmune conditions like MS, although this is purely based on an animal model.
What this does not prove
The study does not establish any effects of minocycline in human MS as it relies solely on animal model results (EAE).
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-09-03
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceMinocycline ameliorates CNS autoimmunity through restraint of CD4+CD11bc+ cells. ↗DOI: 10.3389/fimmu.2026.1823730
Supporting passages (5)
publication datePublication date: 2026-09-03
interventionThe effect of minocycline at the peak of EAE was paralleled with inhibited NO and reactive oxygen species (ROS) production by immune cells in CNS.
primary endpointThe treatment led to immediate reduction of EAE clinical signs, and also to reduction of overall EAE clinical course severity.
findingsTaken together, these data indicate that beneficial effects of minocycline in EAE is primarily based on its ability to limit the generation of ROS and NO in CNS CD4+CD11bc+ cells and that its overall effect on EAE is Nrf2-independent.
limitationsTitle: Minocycline ameliorates CNS autoimmunity through restraint of CD4+CD11bc+ cells.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.